Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intravenous low-dose decitabine versus supportive care in elderly patients with primary myelodysplastic syndrome (MDS) (greater than 10 percent blasts or high-risk cytogenetics), secondary MDS or chronic myelomonocytic leukemia who are not eligible for intensive therapy: an EORTC-German MDS Study Group randomized phase III study.

Next Previous
X
Search
Trial Profile

Intravenous low-dose decitabine versus supportive care in elderly patients with primary myelodysplastic syndrome (MDS) (greater than 10 percent blasts or high-risk cytogenetics), secondary MDS or chronic myelomonocytic leukemia who are not eligible for intensive therapy: an EORTC-German MDS Study Group randomized phase III study.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Decitabine (Primary)
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use

    • Most Recent Events

    • 11 Apr 2011 Final results published in the Journal of Clinical Oncology.
    • 08 Dec 2008 Final results were presented at ASH 2009.
    • 01 Jul 2008 233 patients were enrolled and treated inthis study according to SuperGen media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top